Effect of the dual phosphatidylinositol 3‑kinase/mammalian target of rapamycin inhibitor NVP‑BEZ235 against human Merkel cell carcinoma MKL‑1 cells

Lin,Zhenyu; Mei,Hong; Fan,Jiquan; Yin,Zhongyuan; Wu,Gang

doi:10.3892/ol.2015.3791

Effect of the dual phosphatidylinositol 3‑kinase/mammalian target of rapamycin inhibitor NVP‑BEZ235 against human Merkel cell carcinoma MKL‑1 cells

Authors:
- Zhenyu Lin
- Hong Mei
- Jiquan Fan
- Zhongyuan Yin
- Gang Wu
View Affiliations

Affiliations: Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China, Department of Pediatric Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
Published online on: October 12, 2015 https://doi.org/10.3892/ol.2015.3791
Pages: 3663-3667

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Merkel cell carcinoma (MCC) is an aggressive skin cancer with an increasing incidence. Aberrant activation of the phosphatidylinositol‑3‑kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is common in human cancers and has been revealed to play an important function in cell proliferation, metabolism and tumorigenesis. In the present study, NVP‑BEZ235, a dual PI3K/mTOR inhibitor, was revealed to be effective in inhibiting proliferation and inducing cell cycle arrest in MKL‑1 cells. Additional investigations revealed that NVP‑BEZ235 attenuated PI3K/Akt/mTOR signaling and upregulated the levels of the cell cycle inhibitors p21 and p27. Overall, the present results possess considerable implications for future development of dual PI3K/mTOR inhibitor as potential agents in the management of MCC.

View Figures

View References

1	Muñoz Prieto I, Masferrer Pardo J, Olivera Vegas J, Fortes Alen JR and Pérez Casas AM: Merkel cell carcinoma: what do we know about it and what should we do? Clin Transl Oncol. 14:401–412. 2012. View Article : Google Scholar : PubMed/NCBI
2	Hughes MP, Hardee ME, Cornelius LA, Hutchins LF, Becker JC and Gao L: Merkel cell carcinoma: Epidemiology, target, and therapy. Curr Dermatol Rep. 3:46–53. 2014. View Article : Google Scholar : PubMed/NCBI
3	Koljonen V: Merkel cell carcinoma: Diagnosis, management, and outcomes. Plast Reconstr Surg. 132:894e–895e. 2013. View Article : Google Scholar : PubMed/NCBI
4	Becker JC, Kauczok CS, Ugurel S, Eib S, Bröcker EB and Houben R: Merkel cell carcinoma: Molecular pathogenesis, clinical features and therapy. J Dtsch Dermatol Ges. 6:709–719. 2008. View Article : Google Scholar : PubMed/NCBI
5	Sharma D, Flora G and Grunberg SM: Chemotherapy of metastatic Merkel cell carcinoma: case report and review of the literature. Am J Clin Oncol. 14:166–169. 1991. View Article : Google Scholar : PubMed/NCBI
6	Bartholomeusz C and Gonzalez-Angulo AM: Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets. 16:121–130. 2012. View Article : Google Scholar : PubMed/NCBI
7	Hafner C, Houben R, Baeurle A, Ritter C, Schrama D, Landthaler M and Becker JC: Activation of the PI3K/AKT pathway in Merkel cell carcinoma. PLoS One. 7:e312552012. View Article : Google Scholar : PubMed/NCBI
8	Nardi V, Song Y, Santamaria-Barria JA, et al: Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res. 18:1227–1236. 2012. View Article : Google Scholar : PubMed/NCBI
9	Lin Z, McDermott A, Shao L, Kannan A, Morgan M, Stack BC Jr, Moreno M, Davis DA, Cornelius LA and Gao L: Chronic mTOR activation promotes cell survival in Merkel cell carcinoma. Cancer Lett. 344:272–281. 2014. View Article : Google Scholar : PubMed/NCBI
10	Kong D and Yamori T: Advances in development of phosphatidylinositol 3-kinase inhibitors. Curr Med Chem. 16:2839–2854. 2009. View Article : Google Scholar : PubMed/NCBI
11	Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, et al: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 68:8022–8030. 2008. View Article : Google Scholar : PubMed/NCBI
12	Baumann P, Mandl-Weber S, Oduncu F and Schmidmaier R: The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp Cell Res. 315:485–497. 2009. View Article : Google Scholar : PubMed/NCBI
13	Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, Signoretti S and Mier JW: The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res. 16:3628–3638. 2010. View Article : Google Scholar : PubMed/NCBI
14	Erstad DJ and Jr JC: Mutational analysis of merkel cell carcinoma. Cancers (Basel). 6:2116–2136. 2014. View Article : Google Scholar : PubMed/NCBI
15	Shuda M, Kwun HJ, Feng H, Chang Y and Moore PS: Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator. J Clin Invest. 121:3623–3634. 2011. View Article : Google Scholar : PubMed/NCBI
16	Cho DC: Targeting the PI3K/Akt/mTOR pathway in malignancy: Rationale and clinical outlook. BioDrugs. 28:373–381. 2014. View Article : Google Scholar : PubMed/NCBI
17	Hixon ML, Paccagnella L, Millham R, Perez-Olle R and Gualberto A: Development of inhibitors of the IGF-IR/PI3K/Akt/mTOR pathway. Rev Recent Clin Trials. 5:189–208. 2010. View Article : Google Scholar : PubMed/NCBI
18	Markman B, Dienstmann R and Tabernero J: Targeting the PI3K/Akt/mTOR pathway - beyond rapalogs. Oncotarget. 1:530–543. 2010. View Article : Google Scholar : PubMed/NCBI
19	Hong SW, Shin JS, Moon JH, Kim YS, Lee J, Choi EK, Ha SH, Lee DH, Chung HN, Kim JE, et al: NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotype. Apoptosis. 19:895–904. 2014. View Article : Google Scholar : PubMed/NCBI
20	Masuda M, Shimomura M, Kobayashi K, Kojima S and Nakatsura T: Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines. Oncol Rep. 26:1273–1279. 2011.PubMed/NCBI
21	Oishi T, Itamochi H, Kudoh A, Nonaka M, Kato M, Nishimura M, Oumi N, Sato S, Naniwa J, Sato S, et al: The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma. Oncol Rep. 32:553–558. 2014.PubMed/NCBI
22	Seo BR, Min KJ, Cho IJ, Kim SC and Kwon TK: Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability. PloS One. 9:e955882014. View Article : Google Scholar : PubMed/NCBI
23	Rosich L, Montraveta A, Xargay-Torrent S, López-Guerra M, Roldán J, Aymerich M, Salaverria I, Beà S, Campo E, Pérez-Galán P, et al: Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma. Oncotarget. 5:6788–6800. 2014. View Article : Google Scholar : PubMed/NCBI
24	Wong J, Welschinger R, Hewson J, Bradstock KF and Bendall LJ: Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemia. Oncotarget. 5:10460–10472. 2014. View Article : Google Scholar : PubMed/NCBI
25	Burris HA III: Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol. 71:829–842. 2013. View Article : Google Scholar : PubMed/NCBI
26	Malumbres M and Barbacid M: Cell cycle kinases in cancer. Curr Opin Genet Dev. 17:60–65. 2007. View Article : Google Scholar : PubMed/NCBI
27	Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166. 2009. View Article : Google Scholar : PubMed/NCBI
28	Malumbres M, Hunt SL, Sotillo R, Martín J, Odajima J, Martín A, Dubus P, Ortega S and Barbacid M: Driving the cell cycle to cancer. Adv Exp Med Biol. 532:1–11. 2003. View Article : Google Scholar : PubMed/NCBI
29	Zhou BP, Liao Y, Xia W, Spohn B, Lee MH and Hung MC: Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol. 3:245–252. 2001. View Article : Google Scholar : PubMed/NCBI
30	Yang F, Qian XJ, Qin W, Deng R, Wu XQ, Qin J, Feng GK and Zhu XF: Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma. PloS One. 8:e598792013. View Article : Google Scholar : PubMed/NCBI